As dermatology research advances in both innovation and patient demand, DelRicht Research continues to stand out as a trusted partner for sponsors and CROs conducting vitiligo and other pigmentary disorder trials. With 9 vitiligo studies completed in the past five years, and 4 sites ranked as top enrollers across multicenter programs, our network continues to deliver operational excellence and meaningful outcomes for patients and partners alike.

Trusted Investigators Nationwide

Our physician investigators bring deep expertise across vitiligo and other autoimmune skin conditions, supported by full-time dermatology-dedicated research staff. These teams ensure consistent patient care and protocol adherence while maintaining sensitivity to the psychosocial impacts of vitiligo, an often chronic and visible condition requiring trust and continuity between participants and their care team.

Integrated Patient Support for Retention and Compliance

DelRicht’s dermatology infrastructure spans 7+ active sites nationwide, each fully equipped with secure IP storage, access to local laboratories, and onsite specialty care providers. Our centralized start-up and regulatory teams streamline study activation across multiple regions, ensuring rapid scale-up without compromising on quality. Whether supporting topical, oral, or biologic studies, DelRicht delivers operational consistency from first patient screened to database lock.

Proven Access to Priority Cohorts

Our embedded site model, placing research operations directly within high-volume dermatology and multispecialty clinics, provides immediate access to high-value patient populations. This includes early-stage, moderate-to-severe, and treatment-resistant vitiligo cohorts, as well as patients actively seeking new therapeutic options. Because our network spans diverse communities nationwide, DelRicht also offers strong representation across Fitzpatrick skin types I-VI, ensuring studies capture a comprehensive range of patient experiences and pigmentation patterns. This diversity, particularly among higher Fitzpatrick types, where vitiligo can have more visible and psychosocial impact, enhances both scientific rigor and equity in dermatology research. Our sites maintain an average of 45%+ diversity across dermatology studies, reflecting our ongoing commitment to inclusive enrollment and meaningful outcomes for all populations.

Performance That Moves Medicine Forward

DelRicht Research’s performance speaks for itself. Over the past four years, four of our sites have ranked among top enrollers in industry vitiligo trials, and our teams proudly contributed to the FDA approval of Opzelura® (ruxolitinib) cream, the first and only FDA-approved product for repigmentation in nonsegmental vitiligo. Our experience extends across Psoriasis, Atopic Dermatitis, Eczema, Hidradenitis Suppurativa, Alopecia, Urticaria, Verruca Vulgaris, and beyond, giving sponsors confidence that our network can adapt across dermatologic indications with the same precision and care.

Ready to Accelerate Your Next Vitiligo Trial

DelRicht Research is purpose-built for partnership, combining physician-led expertise, full-service infrastructure, and inclusive patient access to accelerate dermatology trials from start-up through closeout. If you’re seeking a reliable site network to deliver scale, speed, and quality in vitiligo research, we’re ready to help you move medicine forward.